Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Non-steroidal anti-inflammatory drug (NSAID) that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
It was administered orally for the treatment of osteoarthritis, rheumatoid arthritis, acute pain, dysmenorrhea, and migraine until its withdrawal from the market.
It is still available for topical cutaneous application.
Excreted in negligible amounts through breastmilk (Gardiner 2005).
It was withdrawn from the global market in 2004 due to a high risk of cardiovascular toicity (Myocardial infarction, ictus) in people that used it frequently.
Use of preparations for topical application would be compatible with breastfeeding.